scholarly journals Leveraging the Fire Fighter Cancer Cohort Study: Evaluating the association of PFAS exposures with COVID-19 symptoms and antibody response

2021 ◽  
Vol 2021 (1) ◽  
Author(s):  
Jeff Burgess
Keyword(s):  
Cohort Study ◽  
Antibody Response ◽  
Fire Fighter

scholarly journals A cohort study of developmental polychlorinated biphenyl (PCB) exposure in relation to post-vaccination antibody response at 6-months of age

2010 ◽  
Vol 110 (4) ◽  
pp. 388-395 ◽  
Author(s):  
Todd A. Jusko ◽  
Anneclaire J. De Roos ◽  
Stephen M. Schwartz ◽  
B. Paige Lawrence ◽  
Lubica Palkovicova ◽  
...  
Keyword(s):  
Cohort Study ◽  
Antibody Response ◽  
Polychlorinated Biphenyl ◽  
Post Vaccination ◽  
Pcb Exposure

scholarly journals Ambient Air Pollution in Relation to SARS-CoV-2 Infection, Antibody Response, and COVID-19 Disease: A Cohort Study in Catalonia, Spain (COVICAT Study)

2021 ◽  
Vol 129 (11) ◽  
Author(s):  
Manolis Kogevinas ◽  
Gemma Castaño-Vinyals ◽  
Marianna Karachaliou ◽  
Ana Espinosa ◽  
Rafael de Cid ◽  
...  
Keyword(s):  
Air Pollution ◽  
Cohort Study ◽  
Antibody Response ◽  
Ambient Air ◽  
Ambient Air Pollution

scholarly journals Antibody response to SARS-CoV-2 among individuals with IBD diminishes over time: a serosurveillance cohort study

Gut ◽  
2021 ◽  
pp. gutjnl-2021-325238
Author(s):  
Gilaad G Kaplan ◽  
Christopher Ma ◽  
Carmen Charlton ◽  
Jamil N Kanji ◽  
Graham Tipples ◽  
...  
Keyword(s):  
Cohort Study ◽  
Antibody Response ◽  
Over Time

Antibody response toPseudomonas aeruginosain cystic fibrosis patients: A marker of therapeutic success?-A 30-year Cohort study of survival in Danish CF patients after onset of chronicP. aeruginosalung infection

2004 ◽  
Vol 37 (5) ◽  
pp. 427-432 ◽  
Author(s):  
Helle Krogh Johansen ◽  
Lena Nørregaard ◽  
Peter C. Gøtzsche ◽  
Tacjana Pressler ◽  
Christian Koch ◽  
...  
Keyword(s):  
Cystic Fibrosis ◽  
Cohort Study ◽  
Antibody Response ◽  
Therapeutic Success

scholarly journals Comparison of SARS-CoV-2-Specific Antibodies in Human Milk after mRNA-Based COVID-19 Vaccination and Infection

Vaccines ◽  
2021 ◽  
Vol 9 (12) ◽  
pp. 1475
Author(s):  
Hannah G. Juncker ◽  
Sien J. Mulleners ◽  
Marit J. van Gils ◽  
Tom P. L. Bijl ◽  
Christianne J. M. de Groot ◽  
...  
Keyword(s):  
Cohort Study ◽  
Antibody Response ◽  
Human Milk ◽  
Breastfed Infant ◽  
Longitudinal Cohort Study ◽  
Lactating Women ◽  
Longitudinal Cohort ◽  
Specific Antibodies ◽  
Breastfed Infants ◽  
Milk Samples

SARS-CoV-2-specific antibodies are secreted into human milk of infected or vaccinated lactating women and might provide protection to the breastfed infant against COVID-19. Differences in antibody response after these types of exposure are unknown. In this longitudinal cohort study, we compared the antibody response in human milk following SARS-CoV-2 vaccination or infection. We analyzed 448 human milk samples of 28 lactating women vaccinated with the SARS-CoV-2 vaccine BNT162b2 as well as 82 human milk samples of 18 lactating women with a prior SARS-CoV-2 infection. The levels of SARS-CoV-2-specific IgA in human milk were determined over a period of 70 days both after vaccination and infection. The amount of SARS-CoV-2-specific IgA in human milk was similar after SARS-CoV-2 vaccination and infection. After infection, the variability in IgA levels was higher than after vaccination. Two participants with detectable IgA prior to vaccination were analyzed separately and showed higher IgA levels following vaccination compared to both groups. In conclusion, breastfed infants of mothers who have been vaccinated with the BNT162b2 vaccine receive human milk with similar amounts of SARS-CoV-2-specific antibodies compared to infants of previously infected mothers.

scholarly journals A trial platform to assess approved SARS-CoV-2 vaccines in immunocompromised patients: first sub-protocol for a pilot trial comparing the mRNA vaccines Comirnaty® and COVID-19 mRNA Vaccine Moderna®

Trials ◽  
2021 ◽  
Vol 22 (1) ◽  
Author(s):  
Benjamin Speich ◽  
Frédérique Chammartin ◽  
Daniel Smith ◽  
Marcel P. Stoeckle ◽  
Patrizia Amico ◽  
...  
Keyword(s):  
Cohort Study ◽  
Antibody Response ◽  
Pilot Trial ◽  
Type I ◽  
Immunocompromised Patients ◽  
Efficacy And Safety ◽  
Randomized Controlled ◽  
Link Type ◽  
Patient Consent ◽  
Set Up

Abstract Background Late 2019, a new highly contagious coronavirus SARS-CoV-2 has emerged in Wuhan, China, causing within 2 months a pandemic with the highest disease burden in elderly and people with pre-existing medical conditions. The pandemic has highlighted that new and more flexible clinical trial approaches, such as trial platforms, are needed to assess the efficacy and safety of interventions in a timely manner. The two existing Swiss cohorts of immunocompromised patients (i.e., Swiss HIV Cohort Study (SHCS) and Swiss Transplant Cohort Study (STCS)) are an ideal foundation to set-up a trial platform in Switzerland leveraging routinely collected data. Within a newly founded trial platform, we plan to assess the efficacy of the first two mRNA SARS-CoV-2 vaccines that reached market authorization in Switzerland in the frame of a pilot randomized controlled trial (RCT) while at the same time assessing the functionality of the trial platform. Methods We will conduct a multicenter randomized controlled, open-label, 2-arm sub-study pilot trial of a platform trial nested into two Swiss cohorts. Patients included in the SHCS or the STCS will be eligible for randomization to either receiving the mRNA vaccine Comirnaty® (Pfizer/BioNTech) or the COVID-19 mRNA Vaccine Moderna®. The primary clinical outcome will be change in pan-lg antibody response (pan-Ig anti-S1-RBD; baseline vs. 3 months after first vaccination; binary outcome, considering ≥ 0.8 units/ml as a positive antibody response). The pilot study will also enable us to assess endpoints related to trial conduct feasibility (i.e., duration of RCT set-up; time of patient recruitment; patient consent rate; proportion of missing data). Assuming vaccine reactivity of 90% in both vaccine groups, we power our trial, using a non-inferiority margin such that a 95% two-sided confidence interval excludes a difference in favor of the reference group of more than 10%. A sample size of 380 (190 in each treatment arm) is required for a statistical power of 90% and a type I error of 0.025. The study is funded by the Swiss National Science Foundation (National Research Program NRP 78, “COVID-19”). Discussion This study will provide crucial information about the efficacy and safety of the mRNA SARS-CoV-2 vaccines in HIV patients and organ transplant recipients. Furthermore, this project has the potential to pave the way for further platform trials in Switzerland. Trial registration ClinicalTrials.govNCT04805125. Registered on March 18, 2021

Sign in / Sign up

Export Citation Format

Share Document